MedTrace Logo

Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70

NCT00027131 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2008-10-08

No results posted yet for this study

Summary

Description: The trial is designed to determine the response of the immune system of patients with breast cancer to a vaccine made from their own tumor. Researchers believe that this particular vaccine, which is made from purified heat shock proteins taken from each patient's tumor, might alert the body's immune system to recognize and attack invading cancer. To be considered potentially eligible for this study you must be a high risk breast cancer patient and have a tumor that can be removed surgically.

Length/Duration: Vaccinations are administered weekly for six weeks. Follow up visits to the clinic are every three months for two years, then every six months thereafter.

Conditions

  • Breast Neoplasms

Interventions

BIOLOGICAL

Heat Shock Protein 70-peptide complexes (HSP70)

Sponsors & Collaborators

  • UConn Health

    lead OTHER

Principal Investigators

  • Zihai Li, MD, P.hD. · Assistant Professor Medicine & Tumor Immunology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-12-31
Completion
2002-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00027131 on ClinicalTrials.gov